BioPerfectus (SSE: 688399) stands at the forefront of the molecular diagnostics industry, with a specialization in “diagnostics for infectious diseases and women’s and children’s health”. Founded in 2010, BioPerfectus consistently emphasizes R&D, manufacturing, and the distribution of in-vitro diagnostic reagents and instruments. Through strategic planning, the company has seamlessly integrated its efforts from the development and production of upstream core materials to downstream diagnostic services. With a diverse portfolio of over 700 products, BioPerfectus caters to a broad spectrum of medical institutions, CDCs, and independent clinical laboratories across more than 100 countries and regions. Further solidifying its position in molecular diagnostics, BioPerfectus proactively ventures into high-growth areas such as POCT (Point-of-Care Testing). The company’s strategic focus is on expanding applications, refining its product range, and making inroads into international markets. Guided by the vision “To be one of the top global IVD suppliers,”and driven by the mission of “For a healthier future,”BioPerfectus utilizes precise, effective, and streamlined diagnostic techniques with the aim of pioneering advanced early screening and diagnostic methods for infectious diseases and major health challenges, thereby enhancing the quality of life and championing global health.